ArticleCureus2026
A Comparison of Serum Lipase Levels and Clinical Outcome Trends in Hospitalized Pediatric Patients With Acute Pancreatitis: A Single-Center Retrospective Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Serum lipase is widely used for the diagnosis of acute pancreatitis (AP) in pediatric patients; however, its prognostic value remains unclear. Despite limited evidence supporting serial monitoring, lipase levels are frequently trended during hospitalization. This study aimed to evaluate whether trending serum lipase levels are associated with improved clinical outcomes in children hospitalized with AP. Methodology We conducted a single-center retrospective chart review of pediatric patients (0-19 years) admitted with AP at Children's Hospital & Medical Center between January 1, 2021, and December 31, 2022. Diagnosis was based on the INSPPIRE criteria. Patients were categorized into the following two groups: those who had serum lipase levels trended after diagnosis and those who did not. Clinical outcomes, including persistence of abdominal pain, nausea, and/or vomiting at 48 and 96 hours; length of stay (LOS); type of intravenous fluids administered; analgesic use; associated risk factors; and cost of laboratory testing, were analyzed. Results A total of 65 patients met the inclusion criteria. Of these, 77% had serial lipase levels measured. There was no statistically significant difference in symptom persistence at 48 hours (63.8% in trended vs. 78.6% in non-trended; p = 0.35) or at 96 hours (82.9% vs. 100%; p = 0.58). Patients in the trended group had a significantly longer median LOS (4.0 days) compared to the non-trended group (2.5 days) (p = 0.0129). The mean laboratory cost was higher in the trended group ($184.0) compared to the non-trended group ($66.0). No meaningful prognostic correlation was identified between serial lipase levels and clinical improvement. Conclusions Serial trending of serum lipase levels in hospitalized pediatric patients with AP does not provide prognostic value regarding symptom resolution and is associated with increased hospital LOS and higher healthcare costs. Lipase testing should be limited to diagnostic purposes rather than routine monitoring during hospitalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.